GlobalData on MSN9d
Regenxbio and Nippon Shinyaku forge $810m gene therapy deal
Regenxbio will receive $110m upfront from Nippon Shinyaku and is eligible to get up to $700m in development, regulatory, and ...
FierceBiotech10d
RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront
With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now ...
Hosted on MSN17d
RARE's Cholesterol Drug Evkeeza Gains EC Approval for Expanded Use
Ultragenyx Pharmaceutical RARE announced that the European Commission (EC) has expanded the eligible patient population for one of its marketed products, Evkeeza (evinacumab), an ANGPTL3 inhibitor.
Yahoo Finance23d
Global Mucopolysaccharidosis Treatment Market to Witness Robust Growth, Projected to Reach USD 5,014.5 Million by 2035 Growing at a CAGR of 5.9% | FMI
NEWARK, Del, Jan. 02, 2025 (GLOBE NEWSWIRE) -- The global mucopolysaccharidosis treatment market, valued at USD 2,669.1 million in 2024, is estimated to grow at a compound annual growth rate (CAGR ...
A mother's dread: Passing on a destructive gene
Haliza Md Kasim’s eyes widened. Despite having gone through this before with her first son, Yusof, and despite the doctors ...
Regenxbio, Nippon Shinyaku enter commercialization pact for RGX-121
Regenxbio (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment ...
BioPharma Dive10d
Regenxbio licenses gene therapies to Japan’s Nippon Shinyaku
The other treatment, RGX-111, treats another type of mucopolysaccharidosis called Hurler syndrome. It’s earlier in clinical ...
REGENXBIO, Nippon Shinyaku Join For Development, Commercialization Of RGX-121, And RGX-111
REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for ...
REGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS Diseases
REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of ...